Onyema Ogbuagu, CROI 2022: Long-acting Lenacapavir in People with Multidrug Resistant HIV – Week 52 Results
Lenacapavir, a potent first-in-class inhibitor of HIV-1 capsid function, is in development for treatment and prevention of HIV-1 infection. Dr Onyema Ogbuagu (Yale School of Medicine, New Haven, CT, USA) discusses the ongoing phase 2/3 CAPELLA study, investigating lenacapavir in combination with an optimized background regimen treatment-experienced people with HIV-1, with multidrug-resistance and ongoing viremia.
The abstract entitled: ‘Long-Acting Lenacapavir in People with Multidrug Resistant HIV-1: Week 52 Results’ (Abstract #496) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What are the unmet needs of people living with HIV infection? (0:14)
- What is the mechanism of action of lenacapavir and what are its potential advantages over existing HIV therapies? (1:21)
- What were the aims, methodology and findings of the CAPELLA trial? (3:02)
- What will be the next steps in the clinical development of lenacapavir in this indication? (7:57)
Disclosures: Onyema Ogbuagu is on advisory boards for Gilead Sciences and ViiV Healthcare and a speaker’s Bureau participant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Jeffrey Kwong, ACTHIV 2023: Sexual health in older adults living with HIV, clinical considerations for PrEP, and HIV prevention promotion
Sexual health in the aging process is crucial for healthcare professionals to be educated on due to its significant impact on overall well-being and quality of life for older adults living with HIV. In this interview, we speak with Prof. Jeffrey Kwong (Rutgers School of Nursing, Newark, NJ, USA) to explore the importance of addressing […]
Amphotericin B, an oral lipid nanocrystal for cryptococcal meningitis, phase 2 results: David Boulware, ECCMID 2023
Intravenous amphotericin B is a mainstay of treatment in cryptococcal meningitis, in this phase 2 study the efficacy and safety of amphotericin B, a novel, orally absorbed, less-toxic formulation is investigated. It was a pleasure to talk with Prof. David Boulware (University of Minnesota, Minneapolis, USA) to learn more around the prevalence, clinical presentations and […]
Bifast study: efficacy and safety of immediate start of BIC/FTC/TAF after HIV diagnosis: Aws Waleed M. Al-Hayani, ECCMID 2023
After HIV diagnosis, antiretroviral therapy is indicated to be started as early as possible, the phase 4 Bifast study looked at the efficacy and safety of BIC/FTC/TAF when initiated at the first HIV-specialist appointment. In this interview with Dr. Aws Waleed M. Al-Hayani (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) we discuss the controversies surrounding […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!